|
HY-P9951A-1mg
|
MedChemexpress LLC
|
Ranibizumab (anti-VEGF) [CAS 347396-82-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P9951A-10mg
|
MedChemexpress LLC
|
Ranibizumab (anti-VEGF) [CAS 347396-82-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P9951A-5mg
|
MedChemexpress LLC
|
Ranibizumab (anti-VEGF) [CAS 347396-82-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P9951-1mg
|
MedChemexpress LLC
|
Ranibizumab [CAS 347396-82-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P99155-1mg
|
MedChemexpress LLC
|
ZalutuMu mab [CAS 667901-13-5]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99155-10mg
|
MedChemexpress LLC
|
ZalutuMu mab [CAS 667901-13-5]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99155-5mg
|
MedChemexpress LLC
|
ZalutuMu mab [CAS 667901-13-5]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99417-1mg
|
MedChemexpress LLC
|
Abrezekimab [CAS 2043952-59-4]
|
|
|
|
|
HY-P99417-10mg
|
MedChemexpress LLC
|
Abrezekimab [CAS 2043952-59-4]
|
|
|
|
|
HY-P99417-5mg
|
MedChemexpress LLC
|
Abrezekimab [CAS 2043952-59-4]
|
|
|
|
|
HY-P99425-1mg
|
MedChemexpress LLC
|
Afelimomab [CAS 156227-98-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99425-10mg
|
MedChemexpress LLC
|
Afelimomab [CAS 156227-98-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99425-5mg
|
MedChemexpress LLC
|
Afelimomab [CAS 156227-98-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99437-1mg
|
MedChemexpress LLC
|
Anbenitamab [CAS 2367012-88-0]
|
|
|
|
|
HY-P99437-10mg
|
MedChemexpress LLC
|
Anbenitamab [CAS 2367012-88-0]
|
|
|
|
|
HY-P99437-5mg
|
MedChemexpress LLC
|
Anbenitamab [CAS 2367012-88-0]
|
|
|
|
|
HY-P9953-1mg
|
MedChemexpress LLC
|
Certolizumab pegol [CAS 428863-50-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-P9953-10mg
|
MedChemexpress LLC
|
Certolizumab pegol [CAS 428863-50-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-P9953-5mg
|
MedChemexpress LLC
|
Certolizumab pegol [CAS 428863-50-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99115-1mg
|
MedChemexpress LLC
|
Envafolimab [CAS 2102192-68-5]
|
|
Cancer-programmed cell death
|
|
|
HY-P99115-10mg
|
MedChemexpress LLC
|
Envafolimab [CAS 2102192-68-5]
|
|
Cancer-programmed cell death
|
|
|
HY-P99115-5mg
|
MedChemexpress LLC
|
Envafolimab [CAS 2102192-68-5]
|
|
Cancer-programmed cell death
|
|
|
HY-P78099-100ug
|
MedChemexpress LLC
|
Fc gamma RIIIA/CD16a, Human (Biotinylated, HEK293, His-Avi)
|
|
|
|
|
HY-P78099-20ug
|
MedChemexpress LLC
|
Fc gamma RIIIA/CD16a, Human (Biotinylated, HEK293, His-Avi)
|
|
|
|
|
HY-P78099-50ug
|
MedChemexpress LLC
|
Fc gamma RIIIA/CD16a, Human (Biotinylated, HEK293, His-Avi)
|
|
|
|
